555 related articles for article (PubMed ID: 30142696)
21. The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1.
Luef B; Handle F; Kharaishvili G; Hager M; Rainer J; Janetschek G; Hruby S; Englberger C; Bouchal J; Santer FR; Culig Z
Endocr Relat Cancer; 2016 Jun; 23(6):495-508. PubMed ID: 27255895
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of potential regulatory signaling molecules correlate with androgen receptor splice variants AR-V7 and AR-V567es in prostate cancer metastasis.
Kiliccioglu I; Bilen CY; Sozen S; Konac E
Gene; 2021 Mar; 772():145377. PubMed ID: 33359129
[TBL] [Abstract][Full Text] [Related]
23. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer.
Yamamichi F; Shigemura K; Behnsawy HM; Meligy FY; Huang WC; Li X; Yamanaka K; Hanioka K; Miyake H; Tanaka K; Kawabata M; Shirakawa T; Fujisawa M
Scand J Urol; 2014 Dec; 48(6):523-32. PubMed ID: 25356787
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.
Kong D; Sethi S; Li Y; Chen W; Sakr WA; Heath E; Sarkar FH
Prostate; 2015 Feb; 75(2):161-74. PubMed ID: 25307492
[TBL] [Abstract][Full Text] [Related]
25. Cancer stem cell and mesenchymal cell cooperative actions in metastasis progression and hormone resistance in prostate cancer: Potential role of androgen and gonadotropin‑releasing hormone receptors (Review).
Contreras HR; López-Moncada F; Castellón EA
Int J Oncol; 2020 May; 56(5):1075-1082. PubMed ID: 32319606
[TBL] [Abstract][Full Text] [Related]
26. Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition.
Jing Y; Cui D; Guo W; Jiang J; Jiang B; Lu Y; Zhao W; Wang X; Jiang Q; Han B; Xia S
Cancer Lett; 2014 Jun; 348(1-2):135-45. PubMed ID: 24662746
[TBL] [Abstract][Full Text] [Related]
27. ING3 promotes prostate cancer growth by activating the androgen receptor.
Nabbi A; McClurg UL; Thalappilly S; Almami A; Mobahat M; Bismar TA; Binda O; Riabowol KT
BMC Med; 2017 May; 15(1):103. PubMed ID: 28511652
[TBL] [Abstract][Full Text] [Related]
28. Androgen depletion up-regulates cadherin-11 expression in prostate cancer.
Lee YC; Cheng CJ; Huang M; Bilen MA; Ye X; Navone NM; Chu K; Kao HH; Yu-Lee LY; Wang Z; Lin SH
J Pathol; 2010 May; 221(1):68-76. PubMed ID: 20191612
[TBL] [Abstract][Full Text] [Related]
29. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
[TBL] [Abstract][Full Text] [Related]
30. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
31. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.
Izumi K; Fang LY; Mizokami A; Namiki M; Li L; Lin WJ; Chang C
EMBO Mol Med; 2013 Sep; 5(9):1383-401. PubMed ID: 23982944
[TBL] [Abstract][Full Text] [Related]
32. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
[TBL] [Abstract][Full Text] [Related]
33. TM4SF3 and AR: A Nuclear Complex that Stabilizes Both Proteins.
Bhansali M; Zhou J; Shemshedini L
Mol Endocrinol; 2016 Jan; 30(1):13-25. PubMed ID: 26649804
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
35. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
36. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.
Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM
Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391
[TBL] [Abstract][Full Text] [Related]
37. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
[TBL] [Abstract][Full Text] [Related]
38. Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer.
Miao L; Yang L; Li R; Rodrigues DN; Crespo M; Hsieh JT; Tilley WD; de Bono J; Selth LA; Raj GV
Cancer Res; 2017 Jun; 77(11):3101-3112. PubMed ID: 28302679
[TBL] [Abstract][Full Text] [Related]
39. The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth.
Ramamurthy VP; Ramalingam S; Gediya LK; Njar VCO
FEBS J; 2018 Mar; 285(6):1051-1063. PubMed ID: 29323792
[TBL] [Abstract][Full Text] [Related]
40. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
Guo Z; Yang X; Sun F; Jiang R; Linn DE; Chen H; Chen H; Kong X; Melamed J; Tepper CG; Kung HJ; Brodie AM; Edwards J; Qiu Y
Cancer Res; 2009 Mar; 69(6):2305-13. PubMed ID: 19244107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
